Jade Biosciences, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Jade Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $23.64M, a 46.63% decline year-over-year.
- Jade Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $44.28M.
- Jade Biosciences, Inc. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $126.95M.
- Jade Biosciences, Inc. stock issued during period, value, new issues for fiscal 2024 was $23.64M, a 46.63% decline from fiscal 2023.
- Jade Biosciences, Inc. stock issued during period, value, new issues for fiscal 2023 was $44.28M.
- Jade Biosciences, Inc. stock issued during period, value, new issues for fiscal 2021 was $126.94M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $23.64M 10-K · filed 2025-03-27 | |
| 2024-06-30 | $23.64M 10-Q · filed 2024-11-12 | |
| 2023-12-31 | $44.28M 10-K · filed 2025-03-27 | |
| 2023-06-30 | $44.28M 10-Q · filed 2024-11-12 | |
| 2021-12-31 | $126.94M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $126.95M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |